1) Strategy & Leadership
- Merck is focused on maximizing the potential of KEYTRUDA and expanding its oncology leadership while diversifying its pipeline with over 20 new products, representing a commercial opportunity exceeding $70 billion.
- CEO Rob Davis expressed confidence in the company's future, highlighting the rapid pace of clinical and regulatory advancements and the successful execution of their strategic commitments made in 2021.
- The acquisition of Terns Pharmaceuticals was completed to enhance the hematology pipeline, reflecting a disciplined approach to business development aimed at long-term shareholder value.

2) Financial & Segment Results
- Q2 2026 revenue reached $16.6 billion, a 5% increase YoY (4% excluding foreign exchange).
- Key revenue drivers included:
- Oncology: KEYTRUDA sales increased 4% to $8.4 billion.
- Animal Health: Sales grew 5%.
- Vaccines: GARDASIL sales were $1.2 billion, up 3%.
- Cardiometabolic: WINREVAIR sales surged 75% to $588 million.
- Gross margin was 81.1%, down 1.1 percentage points due to higher inventory reserves.
- Operating expenses rose to $12.6 billion, including a $5.7 billion charge for the Terns acquisition.

3) Operational & Product Plans
- Significant product developments included the FDA approval of LIPFENDRA, the first oral PCSK9 inhibitor, aimed at reducing LDL cholesterol.
- Merck's oncology portfolio continues to thrive with multiple approvals for KEYTRUDA and promising data from the sac-TMT program for endometrial cancer.
- The company is advancing its HIV pipeline with IDVYNSO and plans for a monthly oral HIV prep candidate, alimatravir, in Phase III studies.
- Ongoing investments in the pipeline are expected to create long-term value, with a focus on innovative medicines and vaccines.

4) Guidance & Outlook
- Merck raised its full-year revenue guidance to $66.3 billion - $67.3 billion, reflecting growth of 2% to 4%.
- EPS guidance is set between $2.66 and $2.76, including a $2.31 charge from the Terns acquisition.
- The company anticipates a moderate year-over-year growth for KEYTRUDA as it reaches peak penetration across key indications, while also expecting higher other revenue in the second half of 2026 due to a revenue hedging program.

5) Problems / Headwinds
- The company faces challenges in achieving rapid access for LIPFENDRA, with expectations for a slower initial uptake in the primary care setting.
- There are concerns regarding the potential decline in U.S. KEYTRUDA sales growth and the impact of generic competition on BRIDION sales.
- The transcript did not provide specific figures on the performance of certain pipeline products or detailed competitive analysis against peers.

Bottom line: Merck is positioned for sustainable growth with a robust pipeline and strategic focus on innovation, despite facing challenges in market access and competition. The company’s strong Q2 performance and raised guidance reflect confidence in its future trajectory, making it an attractive prospect for shareholders.